赛莫尼克斯制药公司的Lasofoxifene显示,在试验中治疗高级乳腺癌很有希望。 Sermonix Pharmaceuticals' lasofoxifene shows promise in treating advanced breast cancer in trials.

Sermonix制药公司在第二阶段临床试验中报告了其调查药物Lasofoxifene的可喜结果,该临床试验涉及绝经前期和绝经后期地方乳腺癌患者。 Sermonix Pharmaceuticals has reported promising results for its investigational drug, lasofoxifene, in a Phase 2 clinical trial involving premenopausal and postmenopausal patients with locally advanced breast cancer. 该药物表现出良好的耐受性,并有效抑制了Ki67蛋白质,该蛋白质是癌症细胞分裂的标志,同时不影响绝经期前病人的卵巢功能。 The drug showed good tolerance and effectively suppressed the Ki67 protein, a marker of cancer cell division, without affecting ovarian function in premenopausal patients. 这些调查结果支持进一步研究拉索福化芬在乳腺癌治疗中的潜力。 These findings support further research into lasofoxifene's potential in breast cancer treatment.